Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAggressive LymphomasIndolent LymphomasTransplantationDiseaseHodgkin LymphomaMantle Cell LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaStem Cell Transplantation, AutologousSubgroupICD10C81.-C82.-C82.7C82.9C83.0C83.1C83.3C88.0-Z94.80MeSHHodgkin DiseaseTransplantation, AutologousSequenceChemotherapyChemo-substanceCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabChemo-substanceCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabChemo-substanceCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabChemo-substanceCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabNo. Substances6 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionBendamustineCarmustineCiprofloxacinCotrimoxazoleCytarabineDexamethasoneDimetindenEtoposideFosaprepitantGranisetronMelphalanParacetamolPegfilgrastimThiotepaValaciclovirSupportive substanceBalanced Crystalloid SolutionBendamustineCarmustineCiprofloxacinCotrimoxazoleCytarabineDexamethasoneDimetindenEtoposideFosaprepitantGranisetronMelphalanParacetamolPegfilgrastimThiotepaValaciclovirSupportive substanceBalanced Crystalloid SolutionBendamustineCarmustineCiprofloxacinCotrimoxazoleCytarabineDexamethasoneDimetindenEtoposideFosaprepitantGranisetronMelphalanParacetamolPegfilgrastimThiotepaValaciclovirSupportive substanceBalanced Crystalloid SolutionBendamustineCarmustineCiprofloxacinCotrimoxazoleCytarabineDexamethasoneDimetindenEtoposideFosaprepitantGranisetronMelphalanParacetamolPegfilgrastimThiotepaValaciclovirNo. Substances611Protocol classificationTherapy classificationalternativecurrent standardIntensityHochdosis, bei autologer SZTStandard doseTherapy indicationRelapse therapyseveral possibleTherapy phaseautologous stem cell transplantationSalvageTherapy intentioncurativeRisksDiarrheaEmetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHepatotoxicityInfectionsMucositisOral MucositisPyrexia only studiesPublicationAuthorCaballero MDKeil FKirschey SLadetto MDiseaseNHL, HL, Rezidiv, fehlende Remission nach kurativer ChemotherapieNHL oder HL, auto-SZTRefraktäres oder rezidivierendes NHL oder HLrezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2Origin3rd Medical Department for Haematology and Oncology, Hanusch Hospital, Vienna, AustriaDepartment of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzDepartment of Hematology, Hospital Universitario Salamanca, SpanienDepartment of Translational Medicine, University of Eastern Piedmont, Novara, ItalyProtokolle in Überarbeitung 4 protocols foundBEAM - Carmustine 300 / Etoposide 200 / Cytarabine 200 / Melphalan 140, Autologous Stem Cell Transplantation (PID280 V2.2)Revision: BeEAM - Bendamustine 200 / Etoposide 100 / Cytarabine 200 / Melphalan 140, Autologous Stem Cell Transplantation (PID879 V1.1)R-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006 V1.0)Revision: TEAM - Thiotepa 5 / Etoposide 100 / Cytarabine 200 / Melphalan 140, Autologous Stem Cell Transplantation (PID406 V2.1)
